Here are the 10-Q quarterly reports from Electromed, Inc. (ELMD) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ELMD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ELMD filings page.
Electromed, Inc. (ELMD) reported higher revenue and earnings for the three months ended September 30, 2026. Net revenues were $18.682 million, up 10.6% from $16.887 million; homecare revenue was $17.506 million, up 17.6%. Operating income was $3.489 million, up 30.7%, and net income was $2.761 million, up 29.3%, versus $2.136 million. Diluted earnings per share were $0.32, compared with $0.25.
Operating cash flow was $373,000 versus $169,000; cash and cash equivalents were $15.875 million at September 30, 2026, compared with $20.450 million at June 30, 2026. Financing activities used $4.746 million, including $4.328 million for share repurchases. During the quarter, 157,341 shares were purchased under the repurchase authorization; approximately $1.755 million remained under its $10.0 million limit.
The company reported approximately $44.933 million in working capital and said it expects working capital and available credit to provide sufficient liquidity for anticipated needs over the next 12 months. Its $10.0 million revolving credit facility had no principal outstanding as of September 30, 2026, and matures December 16, 2026, if not renewed or replaced.
Electromed, Inc. delivered strong results for the quarter ended March 31, 2026, with net revenues of $18.6 million, up 18.4% from $15.7 million a year earlier. Growth was led by homecare sales and faster expansion in the hospital market.
Quarterly net income rose to $3.0 million from $1.9 million, while diluted EPS increased to $0.35 from $0.21, reflecting higher volumes and improved net revenues per device. Gross margin remained high at about 79%, helping operating income grow faster than sales.
The company ended the period with $17.0 million in cash and no borrowings on its $10 million revolving credit facility, and has active share repurchases, having bought back 151,911 shares for $3.9 million under a $10 million authorization.
Electromed, Inc. reported strong growth for the quarter ended December 31, 2025. Net revenues rose to $18,897,000 from $16,255,000, driven mainly by higher homecare sales and increased productivity per sales representative. Gross margin remained high at about 78% of net revenues.
Net income increased to $2,761,000, up from $1,968,000, with diluted earnings per share improving to $0.32 from $0.22. For the first six months, revenue reached $35,784,000 and net income $4,897,000, both well above the prior year.
The company ended the period with cash and cash equivalents of $13,791,000 and total shareholders’ equity of $45,439,000. It entered a new $10,000,000 secured revolving credit facility with no borrowings outstanding and continued its stock repurchase program, retiring 146,441 shares at an average price of $25.72 per share.
Electromed, Inc. (ELMD) reported stronger Q1 FY2026 results. Net revenues rose 15.1% to $16,887,000, led by homecare ($14,889,000), hospital ($1,047,000), and homecare distributors ($829,000). Gross profit was $13,197,000 at 78.1% of revenue. Operating income increased to $2,670,000 and net income grew 44.9% to $2,136,000, with diluted EPS of $0.25.
SG&A was $10,286,000, reflecting investments in sales, travel, and marketing; R&D was $241,000. Cash and cash equivalents were $14,113,000, and total shareholders’ equity reached $44,745,000. Operating cash flow was $169,000 after seasonal compensation payouts and inventory build; capital expenditures were $252,000. The company has a $2,500,000 revolving credit facility with no borrowings outstanding.
Capital returns: A stock repurchase authorization of up to $10,000,000 was approved on September 9, 2025; during the quarter, 40,848 shares were repurchased for $1,003,000 at an average of $24.57. Shares outstanding were 8,340,538 as of November 5, 2025. Management cites a working capital position of approximately $35,800,000 and states liquidity is sufficient for the next twelve months.